OMERNasdaqPharmaceutical PreparationsFiscal year ends December 31
OMEROS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$16.35+0.15 (+0.93%)
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 209.6% | 120.2% | 2.2% | |
| Return on assets | -114.8% | -86.8% | -1.1% | |
| Current ratio | 3.75 | 4.12 | 2.76 | |
| Debt to equity | -2.13 | – | – | |
| Net debt to EBITDA | -1.44× | – | – | |
| Interest coverage | -6.9× | -5.9× | 127.9× | |
| Inventory turnover | 1.8× | 0.7× | – | |
| Capex to revenue | 0.3% | 0.4% | – | |
| Diluted shares | 40M | 57M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Omeros generated $535.83M from operations and spent $17.55M on capital expenditure, dividends and share buybacks. 6% of that went back into the business.
Generated
$535.83M
Used
$17.55M
Capital expenditure$1.05M6%Dividends$00%Share buybacks$16.51M94%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-187.0%
×Asset turnover0.46×
×Equity multiplier-1.38×
=Return on equity, FY2020120.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2020 | -187.0% | 0.46× | -1.38× | 120.2% |
| FY2019 | -75.6% | 0.96× | -1.11× | 80.8% |
| FY2018 | -424.4% | 0.28× | -2.06× | 246.2% |
| FY2017 | -82.5% | 0.71× | -4.56× | 265.7% |
| FY2016 | -160.4% | 0.72× | -1.83× | 209.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.35M
- Cash generatingOperating cash flow above zero-$116.09M
- Return on assets improvedROA up on the prior year-41.5% → -1.2%
- Earnings backed by cashOperating cash flow above net income-$116.09M vs -$3.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.69 → 2.76
- No dilutionShare count did not rise58M → 64M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –